|
|
|
51-200 employees
View all
|
|
Biotechnology
|
|
139 Main Street,Cambridge,Massachusetts,US
|
|
iTeos Therapeutics | 5,813 followers on LinkedIn. Cancer Immunotherapies by Design | iTeos Therapeutics is a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of highly differentiated immuno-oncology therapeutics for patients. iTeos Therapeutics leverages its deep understanding of the tumor microenvironment and immunosuppressive pathways to design novel product candidates with an aim to improve the clinical benefit of oncology therapies. The innovative pipeline includes two clinical-stage programs targeting novel, validated immuno-oncology pathways designed to build on prior learnings in the field to have differentiated pharmacological and clinical profiles. The most advanced product candidate, EOS-850, is designed as a highly selective small molecule antagonist of the adenosine A2a receptor, in the adenosine triphosphate adenosine pathway, a key driver of immunosuppression in the tumor microenvironment across a broad range of tumors.
|
ITeos Therapeutics Email Formats | Example Email Formats | Percentage |
---|---|---|
{f}{last} | [email protected] |
75.00%
|
The widely used ITeos Therapeutics email format is {f}{last} (e.g. [email protected]) with 75.00% adoption across the company.
To contact ITeos Therapeutics customer service number in your country click here to find.
Michel Detheux is the CEO of ITeos Therapeutics. To contact Michel Detheux email at [email protected] or [email protected].
Find accurate personal emails, work emails and phone numbers for employees
Accelerate prospecting with instant access to 300M professionals from 30M companies with the right contact details.